November 17, 2020
4 min watch
Save
Progress in targeted myeloma therapies ‘amazing’
Healio spoke with Ajay K. Nooka, MD, MPH, FACP, associate professor of hematology and medical oncology at Emory School of Medicine, about exciting progress in anti-BCMA targeted therapies and products in the pipeline.
Click here to watch the next video in the series on significant unmet needs in multiple myeloma.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Nooka reports grant/research support from or advisory committee, review panel or board membership with Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi and Takeda.
Read more about